MX2010001566A - Derivado de aminopirazolamida. - Google Patents

Derivado de aminopirazolamida.

Info

Publication number
MX2010001566A
MX2010001566A MX2010001566A MX2010001566A MX2010001566A MX 2010001566 A MX2010001566 A MX 2010001566A MX 2010001566 A MX2010001566 A MX 2010001566A MX 2010001566 A MX2010001566 A MX 2010001566A MX 2010001566 A MX2010001566 A MX 2010001566A
Authority
MX
Mexico
Prior art keywords
sub
hydrogen atom
aminopyrazole
amide derivative
optionally substituted
Prior art date
Application number
MX2010001566A
Other languages
English (en)
Inventor
Yoshihiro Hoiruchi
Noriko Nunami
Hiroto Tatamidani
Eiko Ohata
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Publication of MX2010001566A publication Critical patent/MX2010001566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Se describe un compuesto representado por la fórmula (1) siguiente, o una sal farmacéuticamente aceptable del mismo, que es útil como agente para la prevención y/o tratamiento de la diabetes, etcétera: (ver fórmula 1) en esta fórmula, RA y RB representan independientemente un grupo alquilo sustituido opcionalmente o similar; RC representa un grupo alquilo sustituido opcionalmente o similar; RD representa un átomo de hidrógeno o similar; RE representa un átomo de hidrógeno o similar; y RF representa un grupo seleccionado de las fórmulas (G1) siguientes: (ver fórmula G1) en donde un átomo de hidrógeno sirve como una rama de enlace, o similar.
MX2010001566A 2007-08-06 2008-08-06 Derivado de aminopirazolamida. MX2010001566A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007204739 2007-08-06
JP2008074895 2008-03-24
PCT/JP2008/064085 WO2009020137A1 (ja) 2007-08-06 2008-08-06 アミノピラゾールアミド誘導体

Publications (1)

Publication Number Publication Date
MX2010001566A true MX2010001566A (es) 2010-03-15

Family

ID=40341369

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001566A MX2010001566A (es) 2007-08-06 2008-08-06 Derivado de aminopirazolamida.

Country Status (11)

Country Link
US (1) US20110071289A1 (es)
EP (1) EP2189449A4 (es)
JP (1) JPWO2009020137A1 (es)
KR (1) KR20100044829A (es)
CN (1) CN101827820A (es)
AU (1) AU2008284746A1 (es)
BR (1) BRPI0815112A2 (es)
CA (1) CA2695437A1 (es)
MX (1) MX2010001566A (es)
RU (1) RU2010108325A (es)
WO (1) WO2009020137A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
CN102633659B (zh) * 2012-02-23 2013-12-04 浙江普洛康裕制药有限公司 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法
JP2015129094A (ja) * 2012-04-16 2015-07-16 大日本住友製薬株式会社 アリールアミノピラゾール誘導体
CN108354933A (zh) 2013-03-15 2018-08-03 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
MX2015011567A (es) * 2013-03-15 2016-04-25 Verseon Corp Halogeno-pirazoles como inhibidores de trombina.
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
CA2960790A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
LT3261639T (lt) 2015-02-27 2022-11-25 Verseon International Corporation Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai
CN111548317A (zh) * 2020-04-28 2020-08-18 苏州纪元康生物科技有限公司 一种依法韦伦合成方法及制备其中间体方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
CN1832741A (zh) 2003-08-07 2006-09-13 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类
US7354938B2 (en) * 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
NZ553159A (en) * 2004-08-30 2010-05-28 Janssen Pharmaceutica Nv N-Adamantan-2-yl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors

Also Published As

Publication number Publication date
CN101827820A (zh) 2010-09-08
JPWO2009020137A1 (ja) 2010-11-04
EP2189449A1 (en) 2010-05-26
US20110071289A1 (en) 2011-03-24
WO2009020137A1 (ja) 2009-02-12
AU2008284746A1 (en) 2009-02-12
KR20100044829A (ko) 2010-04-30
EP2189449A4 (en) 2011-10-19
BRPI0815112A2 (pt) 2015-08-25
CA2695437A1 (en) 2009-02-12
RU2010108325A (ru) 2011-09-20

Similar Documents

Publication Publication Date Title
MX2010001566A (es) Derivado de aminopirazolamida.
WO2009016462A3 (en) Substituted bicyclolactam compounds
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
MX2010002098A (es) Compuesto policiclico.
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TW200728307A (en) Novel spirochromanone derivatives
WO2009020140A1 (ja) アダマンチルウレア誘導体
MY148703A (en) Polycyclic cinnamide derivatives
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2008126889A1 (ja) ヒドラジド化合物及びそれを含有する有害節足動物防除剤
WO2006113552A3 (en) Cyanoarylamines
TW200637539A (en) CTGF inhibitors
MX2009006907A (es) Activador de glucocinasa.
MX2009007482A (es) Agentes antiparasitarios.
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
WO2009038064A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
MX2010006882A (es) Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
WO2007017728A3 (en) Novel heterocyclic compounds
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
MX2009008756A (es) Compuesto macrociclico.
TW200745033A (en) Oxindole derivative as feeding control agent

Legal Events

Date Code Title Description
FA Abandonment or withdrawal